Top 20 Pharmaceutical Companies in the US
Top 20 Pharmaceutical Companies in the US: If you are planning to start your career in the U.S. healthcare industry,
especially as a Pharmaceutical Sales Representative, the first thing you
need to figure out is which companies are actually worth targeting.
Not
every pharmaceutical company in the United States will give you the same
growth, recognition, or paycheck, and from my own observation, choosing
the right one makes all the difference.
That’s exactly why I’ve put together this guide on the Top 20
pharmaceutical companies in the United States. These are the names that
consistently stand out for their market presence, work culture, and the
opportunities they offer to professionals.
By the time you finish reading
this, you’ll have a clear sense of which companies are not only respected
in the industry but also the most promising for building a long-term
career.
Table of content: Top 20 Pharmaceutical Companies in the US
Take a quick look at all the information you can learn here about
companies in the pharma sector-
- Top 20 Pharmaceutical Companies in the US
- Johnson & Johnson
- Merck & Co.
- Pfizer
- AbbVie
- Bristol Myers Squibb – BMS
- Eli Lilly
- Amgen
- Gilead Sciences
- IQVIA
- Regeneron Pharmaceuticals
- Vertex Pharmaceuticals
- Biogen
- Illumina
- Incyte
- Seagen
- Moderna
- United Therapeutics
- Exact Sciences
- Alnylam
- Alkermes
- Pharmaceutical Companies in Key U.S. Cities and States
- FAQs
- Conclusion
Top 20 Pharmaceutical Companies in the US
If you’re planning to build a career in the pharmaceutical or biotech
sector, one of the smartest things you can do is learn about the top
players in the industry. In this field, it’s not just about landing any
job—it’s about working for the companies that are well-respected, offer
strong career growth, and provide competitive salaries.
That’s why I’ve put together this detailed breakdown of the Top 20
pharmaceutical and biotech companies headquartered in the United States.
These organizations are leaders in life sciences and remain some of the
best places to aim for if you want a stable and rewarding career.
I’ll share a little personal note here: In 2023, I had the opportunity to
travel from Bangladesh to the U.S. through my company, since I was already
working in the pharmaceutical industry back home. While in the U.S., I
visited and observed several American pharma companies and even had
conversations with a number of Pharmaceutical Sales Representatives.
The
insights I gathered during that time shaped my understanding of how these
companies operate and which ones really stand out. That’s the perspective
I’m bringing to you here.
Top Pharmaceutical & Biotech Companies (Drug/Biotech Manufacturers)
- Johnson & Johnson (NJ)
- Merck & Co. (NJ)
- Pfizer (NY)
- AbbVie (IL)
- Bristol Myers Squibb – BMS (NY)
- Eli Lilly (IN)
- Amgen (CA)
- Gilead Sciences (CA)
- Regeneron (NY)
- Biogen (MA)
- Vertex Pharmaceuticals (MA)
- Moderna (MA)
- Incyte (DE)
- United Therapeutics (MD)
- Seagen (WA)
- Alnylam (MA)
- Alkermes (MA)
Healthcare / Research Service & Diagnostics Companies
Now, while the following companies don’t manufacture medicines
directly, they play a crucial role in the pharmaceutical ecosystem.
They offer services like clinical trials, diagnostics, genomics, and
healthcare analytics—making them excellent career destinations as
well, especially if you’re interested in the broader healthcare and
biotech landscape.
- IQVIA (NC) → A Contract Research Organization (CRO) and Data Analytics company that supports pharma firms with research, clinical trials, and data management.
- Exact Sciences (WI) → A diagnostics and cancer screening company, best known for its FDA-approved colorectal cancer test, Cologuard.
- Illumina (CA) → A global leader in genomics and DNA sequencing, providing cutting-edge technology that powers research and precision medicine.
Best 10 Pharmaceutical Companies to Work For (Based on Annual Revenue 2024)
When we talk about the largest pharmaceutical companies in the world,
we’re referring to global giants that generate tens of billions of dollars
each year while shaping the future of healthcare. These companies lead the
way in developing medicines, vaccines and cutting-edge biotech
innovations.
What makes them stand out isn’t just their size, but the fact
that their research in areas like oncology, diabetes, immunology,
virology, and neuroscience has already saved—and continues to
save—millions of lives.
In my own experience exploring the U.S. pharmaceutical landscape, I
quickly realized that revenue ranking isn’t just a number. It often
reflects how much a company is investing in research, how strong their
global presence is, and how stable a career path can be if you choose to
work with them.
Here are the ten largest companies dominating the U.S. and global markets:
| Serial | Company Name |
|---|---|
| 1 | Johnson & Johnson |
| 2 | Merck & Co. |
| 3 | Pfizer |
| 4 | AbbVie |
| 5 |
Bristol Myers Squibb – BMS
|
| 6 | Eli Lilly |
| 7 | Amgen |
| 8 | Gilead Sciences |
| 9 | IQVIA ((though a CRO, its revenue size makes it stand alongside pharma giants) |
| 10 | Regeneron Pharmaceuticals |
Companies Ranked 11 to 20 (Based on Annual Revenue 2024)
While the “Top 10” grab most of the headlines, the companies ranked 11 to 20
are equally impressive and often provide outstanding career opportunities. In
fact, many professionals start their journey in these firms, gain experience,
and later transition into the top five or ten.
| Serial | Company Name |
|---|---|
| 11 | Vertex Pharmaceuticals |
| 12 | Biogen |
| 13 | Illumina |
| 14 | Incyte |
| 15 |
Seagen
|
| 16 | Moderna |
| 17 | United Therapeutics |
| 18 | Exact Sciences |
| 19 | Alnylam |
| 20 | Alkermes |
If you’re planning a career in the pharmaceutical industry, focusing on these
Top 20 companies can be a game-changer. They don’t just offer competitive
salaries—they also provide strong career growth, attractive benefits, and the
chance to work on projects that have a real global impact.
Top 10 Most Popular Pharmaceutical Companies in the US (Based on Popularity)
When it comes to choosing a pharmaceutical company to work for, popularity
can be just as important as revenue. A company may be financially huge,
but if it doesn’t have strong brand recognition or trust among doctors and
patients, its influence may not feel the same on the ground.
In the U.S., certain companies stand out not only because of their
blockbuster drugs but also because of how widely they are recognized,
prescribed and trusted. From hospitals and clinics to direct consumer
advertising, these companies are household names in American healthcare.
Based on recent popularity rankings, here are the Top 10 most popular
pharmaceutical companies in the U.S. -
Johnson & Johnson
| Subject | Description |
|---|---|
| Founded by | Johnson & Johnson was founded in 1886 by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson (three brothers) |
| Chairman & CEO | Joaquin Duato |
| Headquarters | One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933, USA |
| Board of Directors | Joaquin Duato (Chair & CEO), Darius Adamczyk, Beckerle, Doudna, Hewson, Paula Johnson, Joly, McClellan, Mulcahy, Weinberger, West, Woods |
| Production Type | Prescription drugs & vaccines, Medical devices & surgical instruments, OTC medicines & personal care (spun off into Kenvue in 2023) |
| Export | Products exported worldwide, sold in over 175 countries |
| Approval | FDA, EMA, WHO and global regulatory approvals. |
| Annual Revenue | Latest Annual Revenue: $88.8 B (2024) |
| Key Products | Stelara, Darzalex, Imbruvica, Remicade; Tylenol, Listerine, Band-Aid (Kenvue) |
| Website | Link |
Merck & Co.
| Subject | Description |
|---|---|
| Founded by | Theodore Weicker & George Merck (U.S. branch in 1891) |
| Chairman & CEO | Robert M. Davis |
| Headquarters | Rahway, New Jersey, US |
| Board of Directors | Robert M. Davis, Douglas M. Baker Jr., Mary Ellen Coe, Pamela J. Craig, Tom Glocer, Surendralal L. Karsanbhai, Risa J. Lavizzo-Mourey, Stephen L. Mayo, Paul B. Rothman, Patricia F. Russo, Christine E. Seidman, Inge G. Thulin, Kathy J. Warden |
| Production Type | Pharmaceuticals, Vaccines, Animal Health |
| Export | Products sold worldwide across all major regions (Americas, EMEA, Asia–Pacific, Latin America) |
| Approval | Products approved by FDA, EMA, and global regulatory agencies (standard for global pharma) (common industry knowledge) |
| Annual Revenue | Latest Annual Revenue: $64.2 B (2024) |
| Key Products |
Oncology: Keytruda, Lynparza, Lenvima, Welireg, Reblozyl
Vaccines: Gardasil, ProQuad/MMRV, Vaxneuvance, RotaTeq, Pneumovax
23
|
| Website | Link |
Pfizer
| Subject | Description |
|---|---|
| Founded by | Charles Pfizer & Charles F. Erhart (1849) |
| Chairman & CEO | Albert Bourla |
| Headquarters | The Spiral, New York City, USA |
| Board of Directors | Independent board (2025) including Shantanu Narayen (Lead Indep. Dir.), Susan Desmond-Hellmann, Scott Gottlieb, Mortimer (Tim) Buckley, Cyrus Taraporevala, Ronald E. Blaylock, James C. Smith, James Quincey, Dan Littman, Susan Hockfield, Suzanne Nora Johnson, Joseph J. Echevarria and Albert Bourla |
| Production Type | Pharmaceuticals & Vaccines (global biopharma) |
| Export | Products sold worldwide (61% revenue from U.S., 39% from other regions including China ~4%) |
| Approval | Products approved by major regulators (FDA, EMA, etc.) — standard for global pharmaceutical products |
| Annual Revenue | Latest Annual Revenue: $63.6 B (2024) |
| Key Products | Eliquis, Prevnar, Paxlovid, Vyndaqel, Comirnaty, Ibrance |
| Website | Link |
AbbVie
| Subject | Description |
|---|---|
| Founded by | Spin-off from Abbott Laboratories (2012) |
| Chairman & CEO | Robert A. Michael (CEO since July 1, 2024; appointed Chairman effective July 1, 2025) |
| Headquarters | North Chicago, Illinois, USA |
| Board of Directors | Independent-led board including Robert A. Michael and multiple independent directors (Lead Independent Director: Roxanne S. Austin, plus members such as Alpern, Davis, Falk, Hart, Quaggin, etc.) |
| Production Type | Biopharmaceuticals (Immunology, Oncology, Neuroscience, Aesthetics, Virology) |
| Export | Products distributed in 170+ countries worldwide |
| Approval | FDA approvals for products like Skyrizi (Ulcerative Colitis), Vyalev (Parkinson’s infusion), Emblaveo (intra-abdominal infection), Emrelis (oncology), plus other global regulatory approvals |
| Annual Revenue | Latest Annual Revenue: $56.33 B (2024) |
| Key Products | Skyrizi, Humira, Rinvoq, Botox, Imbruvica; Venclexta, Mavyret |
| Website | Link |
Bristol Myers Squibb
| Subject | Description |
|---|---|
| Founded by | Merger of Bristol-Myers (founded by William M. Bristol & John R. Myers) and Squibb (founded by Edward R. Squibb) in 1989 |
| Chairman & CEO | Christopher Boerner |
| Headquarters | 345 Park Avenue, New York, NY, USA |
| Board of Directors | Includes Christopher Boerner + independent directors such as Michael R. McMullen (added July 1, 2024) |
| Production Type | Pharmaceuticals and Biologics (focus on oncology, immunology, neuroscience, cardiovascular, virology) |
| Export | Global distribution across Americas, EMEA, Asia-Pacific (standard for global pharma; implied) |
| Approval | Recent FDA approval for schizophrenia drug Cobenfy (2024); also CAR-T therapy Breyanzi approved for CLL/SLL |
| Annual Revenue | Latest Annual Revenue: $48.3 B (2024) |
| Key Products |
Opdivo, Revlimid, Eliquis (core brands)
Sotyktu (deucravacitinib for psoriasis)
Cobenfy (new schizophrenia drug)
|
| Website | Link |
Eli Lilly
| Subject | Description |
|---|---|
| Founded by | Colonel Eli Lilly in 1876 |
| Chairman & CEO | David A. Ricks (CEO and Chair since 2017) |
| Headquarters | Indianapolis, Indiana, USA – 893 S Delaware St, Indianapolis, IN 46225 |
| Board of Directors | Includes David A. Ricks, Jon Moeller (joined Dec 1, 2024), Mary Lynne Hedley, Ralph Álvarez, Gabrielle Sulzberger, and others |
| Production Type | Pharmaceuticals (focus on diabetes, obesity, oncology, immunology) |
| Export | Products sold globally (presence in 125+ countries) |
| Approval | FDA and global regulatory approvals for drugs like Zepbound (sleep apnea), Omvoh (Crohn’s disease), Kisunla (Alzheimer’s), among others |
| Annual Revenue | Latest Annual Revenue: $45.0 B (2024) |
| Key Products |
Metabolic: Mounjaro, Zepbound, Trulicity, Jardiance Oncology: Verzenio Immunology: Taltz, Omvoh Neuroscience: Kisunla |
| Website | Link |
Amgen
| Subject | Description |
|---|---|
| Founded by | Originally founded as Applied Molecular Genetics (Amgen) in 1980 |
| Chairman & CEO | Robert A. Bradway |
| Headquarters | Thousand Oaks, California, USA |
| Board of Directors | Led by Robert A. Bradway along with independent directors (no full list sourced in summary) |
| Production Type | Biopharmaceuticals (focus on oncology, cardiovascular, rare diseases, immunology) |
| Export | Global distribution (implied by product portfolio and global operations) |
| Approval | FDA-approved therapies including Imlygic (oncolytic immunotherapy), Aimovig (migraine prevention), Sotorasib (Lumakras for KRAS G12C cancers) |
| Annual Revenue | Latest Annual Revenue: $33.4 B (2024) |
| Key Products | Prolia, Repatha, Enbrel, Otezla, Tepezza, Evenity, Kyprolis, Nplate, Aranesp |
| Website | Link |
Gilead Sciences
| Subject | Description |
|---|---|
| Founded by | Michael L. Riordan (1987) |
| Chairman & CEO | Daniel O’Day |
| Headquarters | Foster City, California, USA |
| Board of Directors | Daniel O’Day; Jacqueline K. Barton; Jeffrey A. Bluestone; Sandra J. Horning; Kelly A. Kramer; Ted W. Love; Harish Manwani; Javier J. Rodriguez; Anthony Welters (Lead Independent Director) |
| Production Type | Antivirals (HIV, Hepatitis B & C, Influenza, COVID-19); Oncology (cell therapy); Liver disease therapies |
| Export | Global (worldwide operations and sales) |
| Approval | FDA-approved HIV drugs (e.g., Biktarvy, Descovy), lenacapavir (Yeztugo/Yeytuo) for HIV PrEP; Oncology (Trodelvy), others |
| Annual Revenue | Latest Annual Revenue: $28.8 B (2024) |
| Key Products |
HIV: Biktarvy, Descovy Oncology: Trodelvy, Yescarta Liver Disease/COVID: Veklury Prevention (PrEP): Yeztugo (lenacapavir) |
| Website | Link |
IQVIA
Unlike most of the companies on this list, IQVIA is not a pharmaceutical
manufacturer. Instead, it is a Contract Research Organization (CRO)
combined with a health data & analytics leader. IQVIA plays a
supporting role in the pharmaceutical ecosystem by enabling pharma and
biotech firms to develop, test, and commercialize their medicines more
efficiently.
Core Role in Pharma
IQVIA does not produce medicines itself. Rather, it provides critical
services such as:
- Clinical trials management (helping pharma companies test new drugs in humans)
- Data analytics (analyzing real-world evidence & patient data)
- Market research (assessing demand before product launch)
- Healthcare technology & AI solutions (optimizing R&D and patient care)
In short, when global pharma leaders like Pfizer, Johnson & Johnson or AbbVie create breakthrough drugs, IQVIA provides the research
backbone—ensuring trials, data, and insights are accurate and
regulatory-ready.
| Subject | Description |
|---|---|
| Founded by | Dennis Gillings (as Quintiles in 1982; merged with IMS Health in 2016 to form IQVIA) |
| Chairman & CEO | Ari Bousbib |
| Headquarters | Durham, North Carolina, USA |
| Board of Directors | Includes Leader Director John M. Leonard, Leslie Wims Morris, and other independent directors |
| Production Type | Contract Research & Real-World Analytics (Clinical Trials R&D, Technology & Analytics, Commercial & Consulting Services) |
| Export | Global operations in 100+ countries (serving clients worldwide) |
| Approval | Not an FDA regulator; provides CRO and analytics services supporting industry approvals (no direct product approvals) |
| Annual Revenue | Latest Annual Revenue: $15.4 B (2024) |
| Key Products | Technology & Analytics Solutions; Research & Development Solutions; Contract Sales & Medical Solutions |
| Website | Link |
Regeneron Pharmaceuticals
| Subject | Description |
|---|---|
| Founded by | Leonard Schleifer & George Yancopoulos (1988) |
| Chairman & CEO | Leonard Schleifer |
| Headquarters | Tarrytown (Westchester County), New York, USA |
| Board of Directors | Scientific-heavy board (6 of 13 are National Academy members; includes Nobel laureates; led by co-chairs Schleifer & Yancopoulos) |
| Production Type | Biotech—monoclonal antibody & biologics (ophthalmology, immunology, oncology, rare diseases) |
| Export | Global distribution (available in 100+ countries) |
| Approval | Multiple FDA-approved biologics (Eylea, Dupixent, Libtayo, Praluent, Kevzara, Evkeeza, Veopoz, Ordspono, Lynozyfic) |
| Annual Revenue | Latest Annual Revenue: $14.2 B (2024) |
| Key Products |
Ophthalmology: Eylea/Eylea HD; Immunology: Dupixent; Oncology: Libtayo; Rare Biologics: Evkeeza; Hematology: Lynozyfic; Autoimmune: Praluent |
| Website | Link |
Vertex Pharmaceuticals
| Subject | Description |
|---|---|
| Founded by | Michael L. Riordan (1987) |
| Chairman & CEO | Reshma Kewalramani (CEO since 2020) |
| Headquarters | Boston, Massachusetts, USA (based on company operations) |
| Board of Directors | Led by CEO; board includes independent directors (detailed list not summarized) |
| Production Type | Biopharmaceuticals (Cystic Fibrosis therapies, gene therapies, pain medications, etc.) |
| Export | Global distribution (implied by global launches) |
| Approval | FDA-approved: TRIKAFTA (CF therapy), ALYFTREK (CF), CASGEVY (gene-edited therapy for sickle cell), JOURNAVX (non-opioid pain med), Suzetrigine (JOURNAVX) |
| Annual Revenue | Latest Annual Revenue: $11.02 B (2024) |
| Key Products |
CF: TRIKAFTA/KAFTRIO, ALYFTREK
Gene Therapy: CASGEVY
Pain: JOURNAVX (Suzetrigine)
|
| Website | Link |
Biogen
| Subject | Description |
|---|---|
| Founded by | Multiple scientists (Kenneth Murray, Phillip Sharp, Walter Gilbert, Heinz Schaller & Charles Weissmann) in 1978 in Geneva |
| Chairman & CEO | Christopher A. Viehbacher (joined Biogen as CEO in November 2022) |
| Headquarters | Cambridge, Massachusetts, USA (implied from company location) |
| Board of Directors | CEO Christopher Viehbacher leads; board includes independent directors (detailed list not summarised here) |
| Production Type | Biopharmaceuticals focused on neurology, rare diseases, immunology, biosimilars |
| Export | Global (operations and sales worldwide) (implied) |
| Approval | FDA and global approvals for Leqembi (Alzheimer’s), Skyclarys (Friedreich’s ataxia), Qalsody (ALS), Zurzuvae (postpartum depression), Spinraza, among others |
| Annual Revenue | Latest Annual Revenue: $9.68 B (2024) |
| Key Products |
Neurology (MS): Spinraza, Tysabri, Tecfidera;
Rare Diseases: Skyclarys, Qalsody;
Alzheimer’s: Leqembi;
Neuropsychiatry: Zurzuvae
|
| Website | Link |
Illumina
Illumina Inc. is a genomics and biotechnology giant from the United
States, most widely recognized for developing Next-Generation Sequencing
(NGS) technology. While Illumina does not directly manufacture
medicines, its genomic innovations power research and healthcare
breakthroughs across cancer detection, genetic testing, rare diseases,
and precision medicine.
Through its sequencing platforms, scientists and pharmaceutical
companies decode human DNA, study genetic variations, and accelerate the
discovery of new drugs and therapies. Today, Illumina’s technologies are
used in over 150 countries, making it one of the most influential
enablers of modern biomedical science.
| Subject | Description |
|---|---|
| Founded by | Dr. David Walt and Dr. John Stuelpnagel, in 1998. |
| Chairman & CEO | Francis deSouza (CEO since 2016). |
| Headquarters | San Diego, California, USA. |
| Board of Directors | Includes Francis deSouza (CEO); independent directors with diverse backgrounds in genomics, science, and technology. |
| Production Type | Genomics & biotechnology—focuses on next-generation sequencing (NGS) technology and genetic testing for healthcare, research, and life sciences. |
| Export | Global market presence with a wide customer base in over 150 countries. |
| Approval | FDA-approved technologies for clinical diagnostics, including next-gen sequencing instruments and assays for genetic testing. |
| Annual Revenue | Latest Annual Revenue: $4.7 billion (2024). |
| Key Products |
NovaSeq (high-throughput sequencing),
NextSeq (mid-range sequencing),
MiSeq (desktop sequencing),
iSeq (affordable sequencing platform),
GeneRead (NGS-based gene panel testing).
|
| Website | Link |
Incyte
| Subject | Description |
|---|---|
| Founded by | Company founded in 2002 (as Incyte Corporation) |
| Chairman & CEO | Bill Meury (appointed mid-2025, succeeding Hervé Hoppenot) |
| Headquarters | Wilmington, Delaware, USA |
| Board of Directors | Includes CEO and independent directors (details not summarized) |
| Production Type | Pharmaceuticals—focus on oncology, inflammation, autoimmunity, dermatology |
| Export | Global operations and sales (implied by multinational coverage) |
| Approval |
Niktimvo for chronic graft-versus-host disease (FDA-approved 2024)
Zynyz (retifanlimab) for Merkel cell carcinoma (FDA and EU
approved)
|
| Annual Revenue | Latest Annual Revenue: $4.2 B (2024) — 15% YoY growth |
| Key Products |
Dermatology/Inflammation: Jakafi, Opzelura; Oncology/Other: Niktimvo, Zynyz |
| Website | Link |
Seagen
| Subject | Description |
|---|---|
| Founded by | Clay Siegall and Steve Gould in 1998 |
| Chairman & CEO | Clay Siegall (founder, CEO, and Chair as of 2025) |
| Headquarters | Bothell, Washington, USA |
| Board of Directors | Includes Clay Siegall; independent directors like M. Christine Choi; Ken Gabriel; Simon Porte; O. Robin Brown; others |
| Production Type | Biopharmaceuticals—specializing in targeted antibody-drug conjugates (ADCs) for oncology |
| Export | Products distributed globally—FDA approved ADCs available in Europe, Japan, and other regions via partnerships |
| Approval |
Padcev (enfortumab vedotin-ejfv) – urothelial cancer, FDA (2019),
EMA approval (2021).
Tukysa (tucatinib) – HER2-positive breast cancer, FDA (2020), EMA
(2020).
Tivdak (tisotumab vedotin-tftv) – cervical cancer, FDA granted
accelerated approval (2021), European approval (2022).
|
| Annual Revenue | Latest Annual Revenue: Approximately $3.7 billion (2024) |
| Key Products | Oncology ADCs: Padcev, Tukysa, Tivdak, and pipeline programs (phase III ADC candidates) |
| Website | Seagen Secure® Patient Assistance Program, Pfizer + Seagen |
Moderna
| Subject | Description |
|---|---|
| Founded by | Derrick Rossi, Timothy A. Springer, Robert S. Langer, Kenneth R. Chien & Noubar Afeyan (2010) |
| Chairman & CEO | Noubar Afeyan (Chairman), Stéphane Bancel (CEO) |
| Headquarters | Cambridge, Massachusetts, USA |
| Board of Directors | Includes Noubar Afeyan (Chairman) and independent directors (detailed list not summarized) |
| Production Type | mRNA-based vaccines & therapeutics (COVID-19, RSV, flu combos) |
| Export | Global distribution (implied from mRNA vaccine reach) |
| Approval | Spikevax (COVID-19), mRESVIA (RSV) approved |
| Annual Revenue | Latest Annual Revenue: $3.2 B (2024) |
| Key Products | Spikevax, mRESVIA; pipeline: next-gen COVID, combo flu/COVID, RSV vaccine |
| Website | Link |
United Therapeutics
| Subject | Description |
|---|---|
| Founded by | Martine Rothblatt (1996) |
| Chairman & CEO | Martine Rothblatt |
| Headquarters | Co-HQ — Silver Spring, Maryland & Research Triangle Park, North Carolina, USA |
| Board of Directors | Martine Rothblatt; Judy Olian; Louis W. Sullivan; Tommy G. Thompson; Linda Maxwell |
| Production Type | Biotechnology; pulmonary hypertension therapies (treprostinil IV/SC — Remodulin; oral — Orenitram; inhaled — Tyvaso, Tyvaso DPI; PDE-5 inhibitor — Adcirca); oncology (Unituxin); organ-manufacturing/xenotransplantation R&D; EVLP transplant-support services. |
| Export | U.S. and selected international markets — e.g., Remodulin approved in EU (2005) and Japan (2014); initial approvals in U.S./Canada/Israel (2002). |
| Approval | U.S. FDA approvals include Remodulin (2002), Tyvaso (2009), Orenitram (2013), Unituxin (2015), Tyvaso DPI (May 2022); plus EU (EMA) approval for Remodulin (2005) and Japan approval (2014). |
| Annual Revenue | Latest Annual Revenue: $2.88 billion (FY 2024). |
| Key Products |
Pulmonary Hypertension: Tyvaso (nebulized), Tyvaso DPI, Remodulin
(treprostinil), Orenitram (oral treprostinil), Adcirca
(tadalafil); Oncology: Unituxin (dinutuximab). |
| Website | Link |
Exact Sciences
Exact Sciences Corporation is a leading U.S.-based molecular diagnostics
and cancer screening company, best known for its work in early cancer
detection. Unlike traditional pharmaceutical companies that focus on
developing drugs, Exact Sciences specializes in diagnostic solutions
that help doctors identify diseases at an early stage — giving patients
a better chance of successful treatment.
Its flagship product Cologuard is an FDA-approved, non-invasive
stool-based DNA test used to detect colorectal cancer. Beyond Cologuard,
the company has expanded into liquid biopsy technologies and products
like Oncotype DX, which provide oncologists with valuable insights into
cancer progression and treatment options.
| Subject | Description |
|---|---|
| Founded by | Kevin Conroy, Randy Scott, and Sam Gruber (1995) |
| Chairman & CEO | Kevin Conroy (since inception) |
| Headquarters | Madison, Wisconsin, USA |
| Board of Directors | Includes Kevin Conroy (CEO), independent directors (detailed board list not specified in summary sources) |
| Production Type | Diagnostics & Cancer Screening (molecular diagnostics for early cancer detection) |
| Export | U.S.-based operations; products available through partnerships and healthcare networks (primarily U.S. distribution; global reach limited) |
| Approval | FDA-approved diagnostic tests (e.g., Cologuard for colorectal cancer screening) |
| Annual Revenue | Latest Annual Revenue: ~$1.7 B (2024) |
| Key Products | Cologuard (colorectal cancer screening), OncoStat EX (urine-based cancer test), liquid biopsy assays (e.g., Oncotype DX) |
| Website | Link |
Alnylam
| Subject | Description |
|---|---|
| Founded by | Founders’ group incl. Phil Sharp, David Bartel, Tom Tuschl, Paul Schimmel; company formed in 2002 (founding CEO: John Maraganore). |
| Chairman & CEO | Yvonne Greenstreet, MD (CEO since late-2021/Jan 2022). |
| Headquarters | 675 West Kendall St, Cambridge, MA 02142, USA. |
| Board of Directors | See corporate governance page (CEO plus independent directors). |
| Production Type | RNA interference (RNAi) therapeutics for rare/genetic & cardio-metabolic diseases. |
| Export | Global markets (U.S., EU and other regions) via own sales and partners. |
| Approval | Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran); partner Leqvio (inclisiran, Novartis). |
| Annual Revenue | Latest Annual Revenue: $1.65 B “net product revenue” (FY 2024, preliminary/final press release). |
| Key Products | Rare/Genetic: Onpattro, Amvuttra, Givlaari, Oxlumo; Cardio-metabolic (partner): Leqvio (inclisiran). |
| Website | Link |
Alkermes
| Subject | Description |
|---|---|
| Founded by | Dr. Richard Pops, 1987 (originally as a spin-off from MIT). |
| Chairman & CEO | Richard Pops (CEO since 1991; Chair of the board as of now). |
| Headquarters | Dublin, Ireland (Global HQ); U.S. commercial offices in Waltham, MA. |
| Board of Directors | Includes Richard Pops (Chairman, CEO), independent directors from the biotech and financial sectors. |
| Production Type | Biopharmaceuticals—specialized in central nervous system (CNS) disorders, oncology, and addiction therapies. |
| Export | Global reach, with significant operations in North America, Europe, and Asia, in collaboration with major healthcare providers. |
| Approval | FDA-approved treatments like Vivitrol (alcohol and opioid addiction), Aristada (schizophrenia), and Lybalvi (schizophrenia and bipolar disorder). |
| Annual Revenue | Latest Annual Revenue: Approximately $1.5 billion (2024). |
| Key Products |
Vivitrol (alcohol & opioid use disorder),
Aristada (schizophrenia),
Lybalvi (schizophrenia and bipolar disorder),
ALKS 3831 (oncology treatment in pipeline).
|
| Website | Link |
Pharmaceutical Companies in Key U.S. Cities and States
You’ll find a lot of pharmaceutical companies spread across some key cities
and states in the U.S. From Boston and New York to San Diego, Seattle, Texas and Maryland, these areas are home to many of the major players in the
industry.
The list below highlights some of the well-known companies in each
location, giving you a snapshot of where the action is without trying to
include every single company nationwide.
Florida
- Catalyst Pharmaceuticals
- Lupin Pharmaceuticals
San Francisco Bay Area, California
- BioMarin Pharmaceutical
- Genentech
- Gilead Sciences
- Nektar Therapeutics
- Roche Molecular Systems
Chicagoland Area, Illinois
- Abbott Laboratories
- AbbVie
- Amgen Inc.
- Baxter Healthcare
- Danaher Corporation
- Johnson & Johnson
- Takeda Pharmaceutical Company
Philadelphia, Pennsylvania
- AstraZeneca
- GlaxoSmithKline (GSK)
- Endo International
- Johnson & Johnson
- Bristol Myers Squibb
- Teva Pharmaceuticals
Raleigh, North Carolina
- Biogen
- IQVIA
- PPD
- Catalent
- Grifols
- UCB Pharma
New Jersey
- Abbott Laboratories
- Johnson & Johnson
- Merck & Co. (MSD)
- Bristol Myers Squibb
- Organon & Co.
- Sun Pharmaceutical Industries
- Sanofi
- Novartis Pharmaceuticals
Boston / Cambridge, Massachusetts
- Vertex Pharmaceuticals
- Ironwood Pharmaceuticals
- Charles River Laboratories
- Boston Pharmaceuticals
- Sarepta Therapeutics
- Paratek Pharmaceuticals
- Acceleron Pharma
- Agios Pharmaceuticals
- Biogen
- Genzyme
- SAGE Therapeutics
- Moderna
- Blueprint Medicines
- Millennium Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Akebia Therapeutics
- Bluebird Bio
- Vericel Corporation
- BeiGene USA
- Brammer Bio
- Voyager Therapeutics
- Akouos
- Alterome Therapeutics
- Ascidian Therapeutics
- Cellaity
- Delix Therapeutics
- ElevateBio
- Incendia Therapeutics
- Life Biosciences
- MOMA Therapeutics
- Neumora Therapeutics
- Orna Therapeutics
- Remix Therapeutics
- Seaport Therapeutics
- Tessera Therapeutics
New York City / Long Island, New York
- Kadmon Pharmaceuticals
- Ovid Therapeutics
- Bristol Myers Squibb
- Novo Nordisk Inc.
- SmartAnalyst
- Delcath Systems Inc.
- BeyondSpring Pharmaceuticals
- Synergy Pharmaceuticals
- Eli Lilly and Company
- Astellas Pharmaceuticals
- Perrigo
- Zoetis
- ADMA Biologics
- Pfizer
- Merck
- IQVIA
- Cencora
- AstraZeneca
- Novartis
- Bayer
- Sanofi
- GSK
San Diego, California
- AG Scientific
- Ajinomoto Bio-Pharma Services
- Thermo Fisher Scientific
- Bristol Myers Squibb
- Organovo
- Emergent BioSolutions
- Invetech
- Tioga Research
- Illumina
- Sorrento Therapeutics
- Abbott Laboratories
- PSC Biotech
- Rakuten Medical
- BioAgilytix
- Medtronic
- Eli Lilly
- Pfizer
- Grifols
- Cencora
- Merck
- IQVIA
- Eurofins
- Bayer
Seattle, Washington
- A-Alpha Bio
- Adaptive Biotechnologies
- Aurion Biotech
- Lumen Bioscience
- Outpace Bio
- Sound Pharmaceuticals
- Tune Therapeutics
- TwinStrand Biosciences
- Umoja Biopharma
Texas (Houston and Austin)
- Bethyl Laboratories, Inc.
- Agennix
- Moleculin Biotech, Inc.
- Celltex Therapeutics
- Avance Biosciences
- Hope Biosciences
- Ridgeline Therapeutics
- Cavu Biotherapies
- Marker Therapeutics
- Nanospectra Biosciences
- RedVault Biosciences
- Saranas
- Nano3D Biosciences
- InGeneron
- Fagron
- Thermo Fisher Scientific
- Natera
- Genesis Biotechnology Group LLC
- Luminex Corporation
- InVitae
- Grifols
- Signature Science
- Merck KGaA
- Asuragen
- Agilent Technologies
Minneapolis / St. Paul, Minnesota
- Bristol-Myers Squibb
- Bell Pharmaceuticals
- Diamedica
- Regeneron
- OneOme
- North Star Processing
- Takeda Pharmaceuticals
- Fagron
- Otsuka
- InstyMeds
Washington D.C. / Maryland (Bethesda, Rockville, Gaithersburg)
- US Pharmacopeia
- United Therapeutics
- Pharmaceutics International, Inc. (Pii)
- Sirnaomics
- Adaptive Phage Therapeutics
- Wellstat Biologics
- Arcellx
- GenetikSignal
- OncoImmune
- Gain Therapeutics
- AstraZeneca
- Amgen
- Eurofins
- Cencora
- Lonza
- ICON plc
- Otsuka
- PPD
- Parexel
Madison, Wisconsin
- Exact Sciences Corporation
- Catalent Biologics
- Promega Corporation
- Invenra Inc
- Cell Line Genetics
- BioSentinel Pharmaceuticals
- Navitus Health Solutions
- PCI Pharma Services
- Arrowhead Pharmaceuticals
Waltham, Massachusetts/Wilmington, Ohio
- Alkermes
Alkermes has the following locations in the United States:
- Waltham, Massachusetts → Research & Development (R&D) center
- Wilmington, Ohio → Manufacturing (GMP) facility
FAQs
1. Who is the biggest pharmaceutical company in the US?
Johnson & Johnson is currently the biggest pharmaceutical company in
the U.S. by revenue and market influence.
2. Which is the top 5 MNC pharma company?
The Top 5 MNC pharma companies are:
- Johnson & Johnson
- Pfizer
- Merck & Co.
- AbbVie
- Novartis
3. Who is the richest pharma?
Pfizer and Johnson & Johnson are considered among the wealthiest
global pharma companies in terms of revenue and market capitalization.
4. What is the Big 3 in pharma?
In the U.S., the “Big 3” refers to:
- Johnson & Johnson
- Pfizer
- Merck & Co.
5. Is Merck an American company?
Yes, Merck & Co. is an American multinational pharmaceutical company
headquartered in Rahway, New Jersey, USA.
6. What is API in Pharma?
API = Active Pharmaceutical Ingredient, i.e., the core component in a
drug that produces the intended therapeutic effect.
7. Who is the king of pharma?
Johnson & Johnson is often referred to as the “King of Pharma” due
to its scale, product portfolio, and global dominance.
8. Which pharma has the highest salary?
Pfizer, Johnson & Johnson, and Amgen are among the highest-paying
employers in the pharmaceutical industry.
9. Who is the father of pharma?
Galen (Greek physician) is often called the Father of Pharmacy
(ancient).
Friedrich Sertürner (German chemist who isolated morphine) is credited
as a pioneer of modern pharmaceutical sciences.
10. Who is big pharma in the world?
Big Pharma refers to the largest global pharma corporations, typically
including:
- Johnson & Johnson
- Pfizer
- Merck & Co.
- Novartis
- Roche
Conclusion
This brings us to the end of today’s discussion. Hopefully, you now have a clear idea about the Top 20 Pharmaceutical Companies in the US and which ones offer the best salaries and benefits.
Competition in this industry is highly intense, so choosing the right company for your career is extremely important. If needed, seek guidance from experienced Pharmaceutical Sales Representatives who can share real-world insights.
👉 Job switching within the pharmaceutical sector is quite common. Once you join a company and perform well, larger firms often approach you with better offers. That means even if you start with a relatively smaller company, it can still serve as a stepping stone to bigger opportunities.
- For those with strong educational qualifications: applying to Top 10 Pharmaceutical Companies in the US and completing their training programs is the best pathway.
- For those with a weaker academic background: beginning your career with companies ranked between 11 and 20 is a smart choice. This way, you can gain experience, grow professionally, and later move into bigger and more competitive firms.
In short, the pharmaceutical industry offers immense career potential, but success depends on making strategic career choices, continuous learning, and performance excellence.
Sarwar Hossain ✅
I am a travel enthusiast and sports-loving person. Education: BBA & MBA in Accounting.